Prof. PeptideProf. Peptide
Guide

Cagrilintide Dosage in 2026: Trial Doses and What Clinics Report

Cagrilintide is Novo Nordisk's investigational once-weekly amylin analogue. Alone, its phase 2 trial gave 300 to 4,500 mcg (4.5 mg) weekly [1]; its phase 3 trials gave 2,400 mcg (2.4 mg) alongside semaglutide as CagriSema [4]. Clinics publish no cagrilintide dose of their own [5][6][7], and it is not approved anywhere.

No approved dose

Cagrilintide has no label, alone or as CagriSema. The doses below are what its trials administered and what clinics report, as their sources state them [1][4][5].

How is cagrilintide dosed?

Cagrilintide is dosed once weekly in its trials: 300 to 4,500 mcg (4.5 mg) alone in phase 2, after up to 6 weeks of escalation [1], and 2,400 mcg (2.4 mg) with semaglutide in phase 3 [4]. Clinics publish no cagrilintide dose of their own [5][6][7][8]. No trial has set a dose for use outside a study.

  • Clinics describe a once-weekly injection studied only in trials, with no approved dose [5][6][7][8]. None of the eight largest US peptide clinics publishes a cagrilintide dose.
  • Clinics that discuss CagriSema describe its trial schedule, a 16-week build-up from 250 to 2,400 mcg (2.4 mg); that schedule is set out in the CagriSema dosage guide [12].
  • Frequency: once weekly in every source. No clinic publishes a step schedule, maximum dose or course length of its own [5][6][7][8].

Side effects are under What are the side effects of cagrilintide?, its legal status under Is cagrilintide legal?, each trial’s doses under What do human studies show about cagrilintide dosing?, and the combination in CagriSema dosage.

How is cagrilintide taken?

Cagrilintide was administered by subcutaneous injection once weekly in every trial, as self-injections in phase 2 [1] and alongside semaglutide in phase 3 [4]. Its half-life is about 7 to 8 days: 159 to 195 hours given with semaglutide, which its authors called suitable for once-weekly dosing [2], and 186 hours alone with normal kidney function [3].

Given alone, the half-life was 174 hours with normal liver function, and kidney or liver impairment did not change exposure after a single dose [3]. No approved label sets out how it is injected or stored. The cagrilintide reconstitution calculator gives the concentration a given water volume makes in a research-grade vial; it does not set a dose.

What are the side effects of cagrilintide?

Cagrilintide's most frequent side effects in its phase 2 trial were gastrointestinal, such as nausea, constipation and diarrhea, plus injection-site reactions: gastrointestinal events affected 41% to 63% vs 32% on placebo, mainly nausea at 20% to 47% vs 18%, and about 4% stopped for adverse events [1]. No label lists contraindications.

  • Alone, in type 2 diabetes (REIMAGINE 2): adverse events in 82.2% on 2,400 mcg (2.4 mg) vs 70.5% on placebo, mostly gastrointestinal [9].
  • With semaglutide (REDEFINE 1): gastrointestinal events in 79.6% vs 39.9% on placebo, mainly transient and mild to moderate [4].
  • Heart rhythm: in a thorough QT study of 105 healthy people, cagrilintide up to 4,500 mcg (4.5 mg) caused no clinically relevant QTc prolongation [10].

What clinics report

Clinics repeat the trial picture, gastrointestinal effects led by nausea and mostly mild to moderate, plus injection-site reactions, and give no side-effect reports of their own patients [5][6][13].

What do human studies show about cagrilintide dosing?

Cagrilintide's doses have been tested in randomized trials: a phase 2 dose-finding trial of 300 to 4,500 mcg (4.5 mg) weekly alone in 706 adults [1], a phase 1b trial with semaglutide [2], and the CagriSema phase 3 trials at 2,400 mcg (2.4 mg), two of which included a cagrilintide-alone arm [4][9].

Phase 2 dose-finding — cagrilintide alone

NCT03856047

Lancet 2021 [1]

Doses: 706 adults with overweight or obesity: 300, 600, 1,200, 2,400 or 4,500 mcg (1.2, 2.4 and 4.5 mg) once weekly after up to 6 weeks of escalation, placebo, or liraglutide 3,000 mcg (3.0 mg) daily, for 26 weeks [1].

Result: Weight change −6.0% to −10.8% across the five doses vs −3.0% on placebo, with 4,500 mcg (4.5 mg) the highest [1].

Safety: Gastrointestinal events in 41% to 63% vs 32%, mainly nausea (20% to 47% vs 18%), plus injection-site reactions; 10% stopped treatment permanently, similarly across groups, about 4% for adverse events [1].

REDEFINE 1 — with semaglutide (CagriSema), and a cagrilintide-alone arm

NCT05567796

N Engl J Med 2025 [4]

Doses: 3,417 adults randomized 21:3:3:7 to CagriSema 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg), semaglutide alone, cagrilintide 2,400 mcg (2.4 mg) alone, or placebo, once weekly for 68 weeks, including a 16-week escalation [4].

Result: CagriSema −20.4% vs −3.0% on placebo; the abstract gives no figure for the cagrilintide-alone arm [4].

Safety: Gastrointestinal events with CagriSema in 79.6% vs 39.9% on placebo, mainly transient and mild to moderate [4].

REIMAGINE 2 — type 2 diabetes, with a cagrilintide-alone arm

NCT06065540

Lancet Diabetes Endocrinol 2026 [9]

Doses: Adults with type 2 diabetes on metformin: CagriSema at 2,400 mcg (2.4 mg) or 1,000 mcg (1 mg) of each, semaglutide, cagrilintide 2,400 mcg (2.4 mg) alone (n=152), or placebo, for 68 weeks [9].

Result: HbA1c −1.91 points with CagriSema 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg) vs −1.75 with semaglutide 2,400 mcg (2.4 mg) [9].

Safety: Adverse events in 82.2% on cagrilintide 2,400 mcg (2.4 mg) alone vs 70.5% on placebo, mostly gastrointestinal [9].

Phase 1b — with semaglutide

NCT03600480

Lancet 2021 [2]

Doses: 96 adults: cagrilintide 160 to 4,500 mcg (4.5 mg) with semaglutide 2,400 mcg (2.4 mg) [2].

Result: Cagrilintide's half-life was 159 to 195 hours, with a median time to peak of 24 to 72 hours; it did not change semaglutide's exposure [2].

Safety: 37% of 566 adverse events were gastrointestinal, most mild to moderate [2].

Thorough QT study

Diabetes Obes Metab 2024 [10]

Doses: 105 healthy people: cagrilintide escalated to 4,500 mcg (4.5 mg) (n=53) or placebo (n=52) [10].

Result: No clinically relevant QTc prolongation after the last 4,500 mcg (4.5 mg) dose [10].

Safety: No increased risk of ventricular arrhythmia indicated, the authors conclude [10].

FAQ

What is the dosage of cagrilintide?
Cagrilintide has no approved dose. Its phase 2 trial gave 300 to 4,500 mcg (4.5 mg) once weekly by subcutaneous injection, after up to 6 weeks of escalation; the phase 3 trials gave 2,400 mcg (2.4 mg) weekly alongside semaglutide as CagriSema. Clinics publish no cagrilintide dose of their own.
What is the half-life of cagrilintide?
About 7 to 8 days. Given with semaglutide in a phase 1b trial, cagrilintide had a half-life of 159 to 195 hours, which its authors called suitable for once-weekly dosing; given alone in a 2026 study, it was 186 hours with normal kidney function and 174 hours with normal liver function.
How much weight did cagrilintide alone produce?
In its 26-week phase 2 trial in 706 adults, weekly cagrilintide changed weight by −6.0% to −10.8% across 300 to 4,500 mcg (4.5 mg), against −3.0% on placebo, with 4,500 mcg (4.5 mg) the highest. Its phase 3 results are as part of CagriSema, where REDEFINE 1 reported −20.4% vs −3.0%.
What are the side effects of cagrilintide?
Mainly gastrointestinal, such as nausea, constipation and diarrhea, plus injection-site reactions: in the phase 2 trial gastrointestinal events affected 41% to 63% vs 32% on placebo, mainly nausea at 20% to 47% vs 18%, and about 4% stopped for adverse events. A thorough QT study found no clinically relevant QTc prolongation.
Is cagrilintide legal?
Cagrilintide is not approved anywhere, alone or as CagriSema. FDA states it cannot be used in compounding under federal law and is not a component of any approved drug, and clinics describe it as available only in clinical trials. Research-grade cagrilintide is sold for laboratory research use only.

References

  1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160–72. PMID 34798060. NCT03856047. https://pubmed.ncbi.nlm.nih.gov/34798060/
  2. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg: a phase 1b trial. Lancet. 2021;397:1736–48. PMID 33894838. NCT03600480. https://pubmed.ncbi.nlm.nih.gov/33894838/
  3. Nielsen MJF, Becker NP, Duus HHH, et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clin Pharmacokinet. 2026;65:1087–99. PMID 42228334. https://pubmed.ncbi.nlm.nih.gov/42228334/
  4. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393:635–647. PMID 40544433. NCT05567796. https://pubmed.ncbi.nlm.nih.gov/40544433/
  5. Strong Health, South Florida; updated November 3, 2026; read November 4, 2026. Cited for its status and side-effect statements. https://www.stronghealth.com/peptides/cagrilintide/
  6. Superpower; reviewed by William Maish, MD; updated October 5, 2026; read November 4, 2026. Cited for its status and side-effect statements. https://superpower.com/guides/peptides/cagrilintide
  7. TelosRX clinical team, September 1, 2026; read November 4, 2026. Cited for its status statement. https://telosrx.com/blogs/glp1/cagrilintide-vs-semaglutide-comparison
  8. MOPE Clinic, Metairie, Louisiana, September 17, 2025; read November 4, 2026. Cited for its status statement. https://mopeclinic.com/the-legal-status-advantage-and-risks-of-cagrilintide/
  9. Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes Endocrinol. 2026. PMID 42251859. https://pubmed.ncbi.nlm.nih.gov/42251859/
  10. Gabe MBN, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: a thorough QT study in healthy participants. Diabetes Obes Metab. 2024. PMID 39279639. https://pubmed.ncbi.nlm.nih.gov/39279639/
  11. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  12. Second Nature (UK), What is CagriSema? Read November 4, 2026. Cited for its description of the CagriSema trial schedule. https://www.secondnature.io/guides/weight-loss-medications/what-is-cagrisema
  13. Dr. Sue Pedersen, endocrinologist (co-author of the phase 2 trial), November 17, 2021; read November 4, 2026. Cited for her side-effect description. https://drsue.ca/?p=5741
  14. Alabama Board of Medical Examiners, relaying an FDA letter shared through the Federation of State Medical Boards. Read November 4, 2026. https://www.albme.gov/press-release/fda-compounded-drug-products-containing-cagrilintide
  15. World Anti-Doping Agency. The Prohibited List (2026). Valid January 1, 2026. https://www.wada-ama.org/en/prohibited-list

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated